[Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction]
- PMID: 15277727
- DOI: 10.1254/fpj.124.90
[Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction]
Abstract
Randomized aldactone evolution study (RALES) and eplerenone post-AMI heart failure efficacy and survival study (EPHESUS) had shown that aldosterone blockade (AB) with standard therapy resulted in a reduction in mortality in patients with congestive heart failure (CHF) and acute myocardial infarction (AMI). However, the mechanism for the beneficial effect of AB remains unknown. To evaluate the effect of spironolactone (Spi) on left ventricular (LV) remodeling, 34 CHF patients with DCM were randomly divided into the Spi (+) or Spi (-) groups. Four months of treatment with Spi improved the LV volume and mass. To evaluate the effect of Spi on post-infarct LV remodeling, 134 patients with first anterior AMI were randomly divided into the Spi (+) or Spi (-) groups after revascularization. LV ejection fraction was significantly improved after 1 month in the Spi (+) group compared with that in the Spi (-) group. LV end-diastolic volume index was significantly suppressed in the Spi (+) group compared with that in the Spi (-) group. Transcardiac extraction of aldosterone through the heart was significantly suppressed in the Spi (+) group and was significant lower in the Spi (+) group compared with the Spi (-) group. These findings indicate that AB combined with standard therapy can prevent LV remodeling in patients with CHF and AMI, suggesting that the failing heart is the target organ of the aldosterone.
Similar articles
-
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.Circulation. 2003 May 27;107(20):2559-65. doi: 10.1161/01.CIR.0000068340.96506.0F. Epub 2003 May 5. Circulation. 2003. PMID: 12732605 Clinical Trial.
-
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.Circ Heart Fail. 2010 May;3(3):347-53. doi: 10.1161/CIRCHEARTFAILURE.109.906909. Epub 2010 Mar 18. Circ Heart Fail. 2010. PMID: 20299607 Clinical Trial.
-
[Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].J Cardiol. 2004 Feb;43(2):88-91. J Cardiol. 2004. PMID: 15046031 Clinical Trial. Japanese.
-
Aldosterone antagonism and congestive heart failure: a new look at an old therapy.Curr Opin Cardiol. 2004 Jul;19(4):301-8. doi: 10.1097/01.hco.0000129667.34622.14. Curr Opin Cardiol. 2004. PMID: 15218387 Review.
-
[The role of aldosterone-antagonists in the treatment of congestive heart failure].Orv Hetil. 2005 Apr 3;146(14):645-8. Orv Hetil. 2005. PMID: 15889538 Review. Hungarian.
Cited by
-
Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis.Exp Ther Med. 2022 Jun;23(6):369. doi: 10.3892/etm.2022.11296. Epub 2022 Apr 5. Exp Ther Med. 2022. PMID: 35495592 Free PMC article.
